OR WAIT 15 SECS
Agnes Shanley is senior editor of Pharmaceutical Technology.
Bio/pharmaceutical companies are adopting artificial intelligence for discovery, development, risk assessment, safety monitoring, and manufacturing.
Research studies suggest that artificial intelligence (AI) is becoming more widely used within the pharmaceutical industry, and that senior executive support will be crucial to piloting and implementing AI-based approaches to improve R&D efficiency. Industry interviews and an extensive survey (1) by the Tufts Center for the Study of Drug Development (TCSDD), the Drug Information Association (DIA), and eight bio/pharmaceutical manufacturers, has found that pharmaceutical and biopharmaceutical companies are adopting artificial intelligence to help improve functions ranging from discovery and development to risk assessment, safety monitoring, and manufacturing. The research involved interviews with AI experts within the industry, as well as a survey of 402 professionals at pharmaceutical and biopharmaceutical organizations, to assess the current state of AI use and implications for the future.
Survey results found that 70% of respondents use AI in some form, with planning and piloting efforts focused mainly on clinical trials (i.e., patient selection and clinical study recruitment) and identification of data gathering for medicinal products. Research found that staff skills (55%), data structure (52%), and budgets (49%) are currently the greatest obstacles to increased use of AI in pharma. Nearly 60% of survey respondents said that their companies plan to increase staffing over the next two years, to support AI use or implementation.
In addition, TCSDD reports, the survey found that:
“Pharmaceutical and biotechnology companies as well as service providers now rely on AI technologies across all therapeutic areas,” said Mary Jo Lamberti, research assistant professor and associate director of sponsored research at TCSDD. She expects precision medicine and demand for new rare diseases treatments to drive potentially exponential growth in the industry’s use of AI as regulators and industries develop standard policies and regulations to address ethical use, bias, and validation.
Deep Knowledge Analytics released a report that looked at practices at 50 pharmaceutical companies to identify leaders who are most actively driving the use of AI in their organizations (2). The goal is to benchmark the impact of management support on the use of AI, and overall efforts to increase R&D efficiency, according to Margaretta Colangelo, managing partner at Deep Knowledge Ventures. She expects to find a correlation between level of commitment to AI, and market capitalization growth.
1. M.J. Lamberti et al, Clinical Therapy, e-publication, June 24, 2019.
2. Deep Knowledge Analytics, “Pharmaceutical Division Report, AI-Friendly CEOs and Board Members of Pharmaceutical and Technology Corporations,” ai-pharma.dka.global, May 2019.
Supplement: Outsourcing Resources
When referring to this article, please cite it as A. Shanley, “Use of AI is Growing in Pharma,"Pharmaceutical Technology Outsourcing Resources Supplement (August 2019).